{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:07:35Z","timestamp":1791223655672,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174229"],"award-info":[{"award-number":["82174229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["SQ2024YFC3500039"],"award-info":[{"award-number":["SQ2024YFC3500039"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152801","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:35:17Z","timestamp":1754429717000},"page":"152801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data"],"prefix":"10.1016","volume":"74","author":[{"given":"Zihao","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aobo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-3206","authenticated-orcid":false,"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2025.152801_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/BOR.0000000000000679","article-title":"Asymptomatic hyperuricemia: is it really asymptomatic?","volume":"32","author":"Yip","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152801_bib0002","article-title":"Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge","volume":"16","author":"Gu","year":"2025","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.semarthrit.2025.152801_bib0003","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.3390\/nu14173525","article-title":"Gout and diet: a comprehensive review of mechanisms and management","volume":"14","author":"Zhang","year":"2022","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152801_bib0004","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512178","article-title":"Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients","volume":"30","author":"Cicero","year":"2021","journal-title":"Med Princ Pr"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152801_bib0005","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17425255.2023.2287477","article-title":"Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout","volume":"19","author":"Hou","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152801_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152801_bib0007","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s10067-024-06933-4","article-title":"Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis","volume":"43","author":"Wu","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152801_bib0008","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/acr.25309","article-title":"Comparative risk of gout flares when initiating or escalating various urate-lowering therapy: a systematic review with network meta-analysis","volume":"76","author":"Maher","year":"2024","journal-title":"Arthritis Care Res (Hob)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152801_bib0009","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12882-022-02850-3","article-title":"Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials","volume":"23","author":"Sapankaew","year":"2022","journal-title":"BMC Nephrol"},{"issue":"25","key":"10.1016\/j.semarthrit.2025.152801_bib0010","article-title":"Quantitative analysis of the efficacy and associated factors of intra-articular hyaluronic acid with respect to osteoarthritis symptoms: a systematic review of randomized trials and model-based meta-analysis","volume":"S1063-4584","author":"Cao","year":"2025","journal-title":"Osteoarthr Cartil"},{"issue":"24","key":"10.1016\/j.semarthrit.2025.152801_bib0011","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/bjsports-2023-107625","article-title":"Quantitative analysis of effectiveness and associated factors of exercise on symptoms in osteoarthritis: a pharmacodynamic model-based meta-analysis","volume":"58","author":"Han","year":"2024","journal-title":"Br J Sports Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152801_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/psp4.12041","article-title":"The many flavors of model-based meta-analysis: part I-introduction and landmark data","volume":"5","author":"Boucher","year":"2016","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152801_bib0013","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/clpt.2011.256","article-title":"A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis","volume":"90","author":"Mandema","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152801_bib0014","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/psp4.12299","article-title":"Flavors of model-based meta-analysis: part II - modeling summary level longitudinal responses","volume":"7","author":"Boucher","year":"2018","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152801_bib0015","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hob)"},{"key":"10.1016\/j.semarthrit.2025.152801_bib0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.140462","article-title":"Treatment of gout patients with impairment of renal function: a systematic literature review","volume":"92","author":"van Echteld","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152801_bib0017","article-title":"Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease","volume":"10","author":"Sampson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152801_bib0018","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2215\/CJN.05190420","article-title":"Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis","volume":"15","author":"Chen","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152801_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.jrn.2012.08.005","article-title":"Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis","volume":"23","author":"Wang","year":"2013","journal-title":"J Ren Nutr"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152801_bib0020","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3899\/jrheum.150067","article-title":"Effect of urate lowering therapy on renal disease progression in hyperuricemic patients with chronic kidney disease","volume":"42","author":"Kim","year":"2015","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152801_bib0021","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152801_bib0022","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00394-014-0766-0","article-title":"Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies","volume":"53","author":"Aune","year":"2014","journal-title":"Eur J Nutr"},{"issue":"25","key":"10.1016\/j.semarthrit.2025.152801_bib0023","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1080\/10408398.2021.1911928","article-title":"The role of alcohol consumption in pathogenesis of gout","volume":"62","author":"Nieradko-Iwanicka","year":"2022","journal-title":"Crit Rev Food Sci Nutr"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:59:55Z","timestamp":1780120795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"alternative-id":["S0049017225001726"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152801","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152801"}}